Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $82.02M | $40.27M | $45.13M | $35.67M | $20.93M | $7.45M |
| Operating Income | $-82.02M | $-40.27M | $-45.13M | $-35.67M | $-20.93M | $-7.45M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-73.90M | $-35.12M | $-45.24M | $-47.48M | $-20.67M | $-6.55M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-1.53 | $-1.30 | $-1.72 | $-4.24 | $-1.97 | $-0.56 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |